TIDMBELL

Belluscura PLC

31 August 2021

Belluscura PLC

("Belluscura")

American College of Chest Physicians (CHEST) advocates for broader coverage of supplemental oxygen use

LONDON, U.K. AND PLANO, TX, U.S. (31 August 2021). Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology , welcomes the recent statement issued by the American College of Chest Physicians (CHEST) on the rationale for home use of oxygen coverage beyond cluser headacheds.

In response to the US Centers for Medicare & Medicaid Services (CMS) proposed decision on the appropriate use of oxygen for cluster headaches and expanding coverage for the home use of oxygen, CHEST, a worldwide community of over 19,000 clinicians advancing patient care in chest medicine, submitted rationale to CMS to expand the home use of oxygen. The rationale was joined by several other major healthcare organizations including the American Association for Respiratory Care, American Lung Association, COPD Foundation and the American Thoracic Society.

A key rationale for expanding the ability of practitioner is to allow:

"... maximum flexibility of the treating practitioner to determine clinically appropriate oxygen use based on medical need, without the patient having to first try and fail other therapeutic alternatives, is an important change and one that can help improve overall patient care."

The entire rationale can be found on the CHEST website: https://www.chestnet.org/Newsroom/CHEST-News/2021/08/CHEST-advocates-for-broader-coverage-of-supplemental-oxygen-use

Robert Rauker, Belluscura CEO, commented: "This CHEST rationale, following on so closely from the CMS proposals, highlights the expanding demand for home Oxygen, and the increasing opportunity for Belluscura's novel oxygen concentrator technology. Shareholders will be kept fully updated on developments from CHEST and CMS."

For further information please contact:

 
 Belluscura plc                                                          www.belluscura.com 
 Robert Rauker, Chief Executive                                             via Walbrook PR 
  Officer 
 Anthony Dyer, Chief Financial 
  Officer 
 
 SPARK Advisory Partners Limited                                   Tel: +44 (0)20 3368 3550 
  (NOMAD) 
 Neil Baldwin 
 
 Dowgate Capital Limited (Broker)                                  Tel: +44 (0)20 3903 7715 
 James Serjeant / Nicholas Chambers 
 
 Walbrook PR Ltd (Media & Investor    Tel: +44 (0)20 7933 8780 or belluscura@walbrookpr.com 
  Relations) 
 Paul McManus / Sam Allen                            Mob: +44 (0)7980 541 893 / +44 (0)7502 
                                                                                    558 258

About Belluscura plc ( www.belluscura.com )

Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.

About RNS Reach announcements

RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAFLFFDTIIDFIL

(END) Dow Jones Newswires

August 31, 2021 02:00 ET (06:00 GMT)

Belluscura (LSE:BELL)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024 Click aqui para mais gráficos Belluscura.
Belluscura (LSE:BELL)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024 Click aqui para mais gráficos Belluscura.